Evicenter
Kesimpta (ofatumumab) in Relapsing multiple sclerosis
Manufacturer
Novartis Pharmaceuticals Corporation
Prescribing information
Kesimpta (opens in a new tab)
Questions
73
Last updated

All questions

Safety: Kesimpta (ofatumumab) in relapsing multiple sclerosis

18 questions · 3 sources

Warnings

What are the contraindications for Kesimpta?

Does Kesimpta increase the risk of infections?

Can Kesimpta cause hepatitis B reactivation?

Can Kesimpta cause PML (progressive multifocal leukoencephalopathy)?

Can Kesimpta cause liver problems?

Side effects

What are the most common side effects of Kesimpta?

How often did patients stop Kesimpta because of side effects (ASCLEPIOS)?

Monitoring

Does Kesimpta lower immunoglobulin (IgG and IgM) levels?

Note: The kesimptahcp.com safety page states that 14.3% of KESIMPTA-treated patients in the ASCLEPIOS trials experienced a decrease in IgM. In the Prescribing Information, 14.3% is the proportion whose serum IgM fell below 0.34 g/L, and 7.7% is the proportion with a reported decrease in IgM.

Administration reactions

How common are Kesimpta injection reactions?

How are Kesimpta injection-related and hypersensitivity reactions managed?

Safety

Have nonclinical carcinogenicity or mutagenicity studies been done for Kesimpta?

Does Kesimpta cause anti-drug antibodies (immunogenicity)?

Safety evidence

What are the long-term infection and immunoglobulin effects of Kesimpta (ALITHIOS)?

What happened to Kesimpta patients with COVID-19 in ALITHIOS (through September 2022)?

Vaccines

When should vaccines be given before starting Kesimpta?

Can patients get live vaccines while taking Kesimpta?

What COVID-19 mRNA vaccine antibody response was seen with Kesimpta (Phase 4 study)?

Note: The brochure cites these interim results to a poster presented at the ACTRIMS Forum, February 24-26, 2022.

Can infants exposed to Kesimpta during pregnancy get live vaccines?